מאמרים

European, randomized, phase 3 study
of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D et al. Eur Neuropsychopharmacol. 2013.

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD:

A Phase IV, 2-Year, Open-Label Study in Europe
Coghill DR, et al. CNS Drugs. 2017

Health-related quality of life and functional

outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. Banaschewski T et al. CNS Drugs. 2014.

The World Federation of ADHD

International Consensus Statement: 208 Evidence-based conclusions about the disorder. Faraone SV et al. Neurosci Biobehav Rev. 2021.